Spinal muscular atrophy (SMA) can be fatal, but whether it is depends heavily on the type. The most severe forms kill infants within weeks or months, while the mildest form causes only modest weakness and has little impact on lifespan. Treatments approved in recent years have dramatically changed the outlook, particularly for infants diagnosed early.
Why SMA Is Life-Threatening
SMA is a genetic condition that destroys motor neurons, the nerve cells responsible for controlling muscles. As those neurons die, muscles weaken progressively. The muscles most dangerous to lose are the ones you breathe with. Weakness in the chest wall and diaphragm reduces the volume of air the lungs can move, and the muscles that protect the airway during swallowing weaken too, allowing food or saliva into the lungs.
Respiratory failure is the primary cause of death across all severe forms of SMA. The problem worsens during sleep, when breathing naturally becomes shallower. In people with SMA, the brain’s oxygen-sensing reflexes are also less responsive than normal, so the body compensates poorly when oxygen drops or carbon dioxide builds up overnight. Over time, repeated lung infections, progressive chest deformity from scoliosis, and collapsing air sacs in the lungs compound the problem.
How Severity Varies by Type
SMA is classified into five types based on when symptoms appear and how severe they are. The earlier symptoms start, the more dangerous the disease.
Type 0 is the rarest and most severe form. It begins before birth, with reduced fetal movement detectable during pregnancy. Newborns with type 0 are profoundly weak, never breathe on their own, and need mechanical ventilation from the moment of delivery. Death typically occurs within the first month of life, often within days.
Type 1 is the most common severe form, appearing within the first six months of life. Babies with type 1 cannot sit independently and progressively lose the ability to swallow and breathe. Without treatment or breathing support, most die before age 2. In one Thai cohort of 37 children with type 1, about 78% died. The roughly 22% who survived all required invasive ventilation, with a median age of 5.3 years at the time of the study.
Type 2 appears between 6 and 18 months. Children with type 2 can usually sit but never walk independently. Respiratory complications remain the leading cause of death, but the decline is slower than in type 1. With breathing support, many people with type 2 live into their 20s, 30s, or beyond.
Type 3 starts after 18 months, often in early childhood. Children with type 3 can walk at some point, though many eventually need a wheelchair. Life expectancy is near normal.
Type 4 begins in adulthood, typically after age 30, and causes mild motor impairment. It is very rare and does not significantly shorten life.
The Role of SMN2 Gene Copies
SMA is caused by a missing or broken SMN1 gene. Everyone also carries a backup gene called SMN2, which produces a small amount of the same protein. The number of SMN2 copies a person has strongly predicts how severe their disease will be.
People with only two copies of SMN2 tend to develop symptoms earliest and fare worst. In one study of 40 patients, half of those with two SMN2 copies died, a mortality rate 6.2 times higher than in patients with three copies. No deaths occurred among patients with four copies. More copies mean more backup protein, which partially compensates for the missing gene and produces a milder form of the disease.
How Treatments Have Changed the Outlook
Before 2016, SMA had no approved treatments. Supportive care, especially breathing assistance and nutritional support through feeding tubes, could extend life but could not slow the underlying nerve damage. That changed with the arrival of three disease-modifying therapies that either boost the backup SMN2 gene’s output or replace the missing SMN1 gene entirely.
The impact has been striking. Children with type 1 SMA who once never sat are now reaching motor milestones that were previously unheard of in the natural history of the disease. In a large population study of 342 children treated with gene therapy across Germany, Austria, and Switzerland, only 6 children (1.7%) died during the observation period. Among those treated before symptoms appeared, none required breathing or nutritional support afterward.
Timing matters enormously. Children treated within their first six weeks of life had far better outcomes than those treated later. The probability of needing breathing or feeding support rose significantly with each month of age at the time of treatment. This is because motor neurons, once lost, cannot be recovered. Treatment works by preserving the neurons that remain.
Why Newborn Screening Matters
Because early treatment produces dramatically better results, newborn screening programs have become critical. SMA can be detected through a simple blood test taken from a heel prick at birth, well before any symptoms appear.
A federal evidence review projected that universal newborn screening in the United States could prevent roughly 33 deaths per year among infants with type 1 SMA compared to waiting for symptoms to prompt a clinical diagnosis. It could also avert the need for permanent mechanical ventilation in dozens of additional children. Most U.S. states now include SMA in their newborn screening panels.
Breathing Support and Long-Term Survival
For people with types 2 and 3, non-invasive ventilation (a mask worn during sleep or parts of the day, rather than a surgical breathing tube) plays a major role in extending life. In one study, two-thirds of patients responded well to long-term non-invasive ventilation, with an estimated survival of about 23 years without needing a tracheostomy. The remaining third, who responded poorly, had a median survival of only 5.5 years before requiring more invasive intervention.
The key difference was timing. Patients who started ventilation support early, while their breathing was still relatively stable, did far better than those who began only after an acute respiratory crisis. Starting proactively, rather than reactively, was associated with a sevenfold lower risk of poor outcomes.
Hospitalization rates reflected the same pattern. Patients who responded well to ventilation averaged fewer than one hospital admission per decade, while poor responders were hospitalized roughly once every three years.
What This Means in Practice
SMA is no longer the uniformly fatal diagnosis it was a generation ago, at least for types 1 through 3. Type 0 remains lethal. Type 4 was never life-threatening. For the types in between, the combination of disease-modifying drugs, early detection through newborn screening, and proactive breathing support has fundamentally altered the trajectory. Children diagnosed at birth and treated within weeks now have realistic prospects of sitting, and in some cases walking, milestones that would have been impossible just ten years ago.
The severity still depends on the type, the number of backup gene copies, and how quickly treatment begins. For families facing an SMA diagnosis, the single most important factor is speed: the sooner treatment starts, the more motor neurons are preserved, and the better the long-term outcome.